Novelix Pharmaceuticals Limited (BOM:536565)
69.00
-1.05 (-1.50%)
At close: Nov 16, 2026
Novelix Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 46.58 | 25.57 | 0.85 | 0.1 | -0.6 | -20.27 |
Depreciation & Amortization | 2.71 | 0.98 | 0.38 | 0.38 | 0.56 | 0.8 |
Other Amortization | 0.04 | 0.04 | - | - | - | 0.22 |
Loss (Gain) From Sale of Assets | - | - | - | - | - | 4.57 |
Loss (Gain) From Sale of Investments | - | - | - | - | - | 15 |
Other Operating Activities | 10.86 | 8.15 | 0.23 | -2.97 | -5.14 | 4.6 |
Change in Accounts Receivable | -1,255 | -436.32 | -225.94 | 3.3 | -16.52 | 22.79 |
Change in Inventory | -122.15 | -135.89 | 3.51 | -3.74 | -2.89 | -0.7 |
Change in Accounts Payable | 1,008 | 310.53 | 84.12 | -0.52 | 0.53 | -11.15 |
Change in Other Net Operating Assets | 5.68 | 3.07 | - | - | - | - |
Operating Cash Flow | -303.3 | -223.89 | -136.85 | -3.43 | -24.05 | 15.86 |
Operating Cash Flow Growth | - | - | - | - | - | -0.42% |
Investing Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -58.47 | -32.56 | -1.06 | - | -0.04 | -17.98 |
Sale of Property, Plant & Equipment | - | - | - | 0.18 | - | - |
Investment in Securities | - | - | 30.21 | -1.39 | 22.84 | 15.08 |
Other Investing Activities | 20.89 | 15.33 | 0.16 | 3.07 | -22.04 | -4.69 |
Investing Cash Flow | -37.58 | -17.23 | 29.3 | 1.86 | 0.75 | -7.6 |
Financing Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Debt Issued (Repaid) | 7.73 | - | - | - | - | - |
Issuance of Common Stock | 334.5 | 263.93 | 30.65 | - | - | - |
Other Financing Activities | 16.3 | - | 82.5 | - | - | - |
Financing Cash Flow | 358.53 | 263.93 | 113.15 | - | - | - |
Net Cash Flow
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Miscellaneous Cash Flow Adjustments | - | - | - | 0 | - | -0 |
Net Cash Flow | 17.65 | 22.8 | 5.61 | -1.57 | -23.3 | 8.26 |
Free Cash Flow
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -361.77 | -256.45 | -137.91 | -3.43 | -24.1 | -2.12 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -23.30% | -19.38% | -44.87% | -7.58% | -125.49% | -2.38% |
Free Cash Flow Per Share | -12.88 | -12.16 | -13.86 | -0.33 | -2.98 | -0.26 |
Levered Free Cash Flow | -401.5 | -244.56 | -159.5 | 4.48 | 10.27 | -12.33 |
Unlevered Free Cash Flow | -399.82 | -244.42 | -159.5 | 4.48 | 10.27 | -11.97 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Change in Working Capital | -363.49 | -258.62 | -138.3 | -0.96 | -18.87 | 10.94 |